利伐沙班的副作用有哪些？

Also called Xarelto, its main ingredient is rivaroxaban, which is a highly selective oral drug that directly inhibits factor Xa. The main clinical indications are: 1. For the prevention of venous thrombosis (VTE) in adult patients undergoing elective hip or knee replacement surgery. 2. Indicated to treat venous thrombosis (DVT) in adults and reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT. 3. For use in adult patients with nonvalvular atrial fibrillation who have one or more risk factors (e.g., congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, history of stroke or transient ischemic attack) to reduce the risk of stroke and systemic embolism.

Rivaroxaban is a highly selective, oral drug that directly inhibits factor Xa. By inhibiting factor Rivaroxaban does not inhibit thrombin (activated factor II) and has no proven effect on platelets. A dose-dependent inhibition of factor Xa activity by rivaroxaban has been observed in humans. The effect of rivaroxaban on prothrombin time (PT) has a dose-effect relationship. If NeopLastin is used for content measurement, it is closely related to the plasma concentration (correlation coefficient is 0.98). Different results may occur with other reagents. Reading the PT should be completed within seconds because the International Normalized Ratio (INR) is calibrated and validated only for coumarins and not for other anticoagulants.

But any drug will have side effects after long-term use. So what are the side effects of taking rivaroxaban?

The following is a relevant introduction: 1. Bleeding risk; in the ROCKET AF trial, the most common adverse reaction related to permanent discontinuation was bleeding events, with an incidence rate of 4.3% in the Xarelto group and 3.1% in the warfarin group. The incidence of discontinuation due to non-hemorrhagic adverse events was similar in both treatment groups. 2. Spinal/epidural hematoma. 3. The risk of stroke increases after early discontinuation of medication in patients with valvular atrial fibrillation; 4. Blood and lymphatic system diseases: agranulocytosis, thrombocytopenia; 5. Gastrointestinal diseases: retroperitoneal hemorrhage; 6. Hepatobiliary diseases: jaundice, cholestasis, hepatitis (Including liver cell damage); 7. Immune system diseases: hypersensitivity reaction, allergic reaction, anaphylactic shock, angioedema; 8. Nervous system diseases: cerebral hemorrhage, subdural hematoma, epidural hematoma, hemiparesis; 9. Skin and subcutaneous tissue: Stevens-Johnson syndrome.

Patients should not panic if side effects occur after taking the medicine. Please immediately follow the doctor's instructions and pay attention to medication safety.